Cargando…

COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease – A cross-sectional study in Hungary

INTRODUCTION: Coronavirus infection is a particular risk for patients with chronic obstructive pulmonary disease (COPD), because they are much more likely to become severely ill due to oxygen supply problems. Primary prevention, including COVID-19 vaccination is of paramount importance in this disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Fekete, Monika, Horvath, Alpar, Santa, Balazs, Tomisa, Gabor, Szollosi, Gergo, Ungvari, Zoltan, Fazekas-Pongor, Vince, Major, David, Tarantini, Stefano, Varga, Janos Tamas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671791/
https://www.ncbi.nlm.nih.gov/pubmed/36424256
http://dx.doi.org/10.1016/j.vaccine.2022.11.020
_version_ 1784832623669936128
author Fekete, Monika
Horvath, Alpar
Santa, Balazs
Tomisa, Gabor
Szollosi, Gergo
Ungvari, Zoltan
Fazekas-Pongor, Vince
Major, David
Tarantini, Stefano
Varga, Janos Tamas
author_facet Fekete, Monika
Horvath, Alpar
Santa, Balazs
Tomisa, Gabor
Szollosi, Gergo
Ungvari, Zoltan
Fazekas-Pongor, Vince
Major, David
Tarantini, Stefano
Varga, Janos Tamas
author_sort Fekete, Monika
collection PubMed
description INTRODUCTION: Coronavirus infection is a particular risk for patients with chronic obstructive pulmonary disease (COPD), because they are much more likely to become severely ill due to oxygen supply problems. Primary prevention, including COVID-19 vaccination is of paramount importance in this disease group. The aim of our study was to assess COVID-19 vaccination coverage in COPD patients during the first vaccination campaign of the COVID-19 pandemic. METHODS: A cross-sectional observational study (CHANCE) has been conducted in COPD patients in the eastern, western and central regions of Hungary from 15th November 2021. The anthropometric, respiratory function test results and vaccination status of 1,511 randomly selected patients were recorded who were aged 35 years and older. RESULTS: The median age was 67 (61–72) years, for men: 67 (62–73) and for women: 66 (60–72) years, with 47.98 % men and 52.02 % women in our sample. The prevalence of vaccination coverage for the first COVID-19 vaccine dose was 88.62 %, whereas 86.57 % of the patients received the second vaccine dose. When unvaccinated (n = 172) and double vaccinated (n = 1308) patients were compared, the difference was significant both in quality of life (CAT: 17 (12–23) vs 14 (10–19); p < 0.001) and severity of dyspnea (mMRC: 2 (2–2) vs 2 (1–2); p = 0.048). The COVID-19 infection rate between double vaccinated and unvaccinated patients was 1.61 % vs 22.67 %; p < 0.001 six months after vaccination. The difference between unvaccinated and vaccinated patients was significant (8.14 % vs 0.08 %; p < 0.001) among those with acute COVID-19 infection hospitalized. In terms of post-COVID symptoms, single or double vaccinated patients had significantly fewer outpatient hospital admissions than unvaccinated patients (7.56 vs 0 %; p < 0.001). CONCLUSION: The COVID-19 vaccination coverage was satisfactory in our sample. The uptake of COVID-19 vaccines by patients with COPD is of utmost importance because they are much more likely to develop severe complications.
format Online
Article
Text
id pubmed-9671791
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Authors. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-96717912022-11-18 COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease – A cross-sectional study in Hungary Fekete, Monika Horvath, Alpar Santa, Balazs Tomisa, Gabor Szollosi, Gergo Ungvari, Zoltan Fazekas-Pongor, Vince Major, David Tarantini, Stefano Varga, Janos Tamas Vaccine Article INTRODUCTION: Coronavirus infection is a particular risk for patients with chronic obstructive pulmonary disease (COPD), because they are much more likely to become severely ill due to oxygen supply problems. Primary prevention, including COVID-19 vaccination is of paramount importance in this disease group. The aim of our study was to assess COVID-19 vaccination coverage in COPD patients during the first vaccination campaign of the COVID-19 pandemic. METHODS: A cross-sectional observational study (CHANCE) has been conducted in COPD patients in the eastern, western and central regions of Hungary from 15th November 2021. The anthropometric, respiratory function test results and vaccination status of 1,511 randomly selected patients were recorded who were aged 35 years and older. RESULTS: The median age was 67 (61–72) years, for men: 67 (62–73) and for women: 66 (60–72) years, with 47.98 % men and 52.02 % women in our sample. The prevalence of vaccination coverage for the first COVID-19 vaccine dose was 88.62 %, whereas 86.57 % of the patients received the second vaccine dose. When unvaccinated (n = 172) and double vaccinated (n = 1308) patients were compared, the difference was significant both in quality of life (CAT: 17 (12–23) vs 14 (10–19); p < 0.001) and severity of dyspnea (mMRC: 2 (2–2) vs 2 (1–2); p = 0.048). The COVID-19 infection rate between double vaccinated and unvaccinated patients was 1.61 % vs 22.67 %; p < 0.001 six months after vaccination. The difference between unvaccinated and vaccinated patients was significant (8.14 % vs 0.08 %; p < 0.001) among those with acute COVID-19 infection hospitalized. In terms of post-COVID symptoms, single or double vaccinated patients had significantly fewer outpatient hospital admissions than unvaccinated patients (7.56 vs 0 %; p < 0.001). CONCLUSION: The COVID-19 vaccination coverage was satisfactory in our sample. The uptake of COVID-19 vaccines by patients with COPD is of utmost importance because they are much more likely to develop severe complications. The Authors. Published by Elsevier Ltd. 2023-01-04 2022-11-18 /pmc/articles/PMC9671791/ /pubmed/36424256 http://dx.doi.org/10.1016/j.vaccine.2022.11.020 Text en © 2022 The Authors. Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Fekete, Monika
Horvath, Alpar
Santa, Balazs
Tomisa, Gabor
Szollosi, Gergo
Ungvari, Zoltan
Fazekas-Pongor, Vince
Major, David
Tarantini, Stefano
Varga, Janos Tamas
COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease – A cross-sectional study in Hungary
title COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease – A cross-sectional study in Hungary
title_full COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease – A cross-sectional study in Hungary
title_fullStr COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease – A cross-sectional study in Hungary
title_full_unstemmed COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease – A cross-sectional study in Hungary
title_short COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease – A cross-sectional study in Hungary
title_sort covid-19 vaccination coverage in patients with chronic obstructive pulmonary disease – a cross-sectional study in hungary
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671791/
https://www.ncbi.nlm.nih.gov/pubmed/36424256
http://dx.doi.org/10.1016/j.vaccine.2022.11.020
work_keys_str_mv AT feketemonika covid19vaccinationcoverageinpatientswithchronicobstructivepulmonarydiseaseacrosssectionalstudyinhungary
AT horvathalpar covid19vaccinationcoverageinpatientswithchronicobstructivepulmonarydiseaseacrosssectionalstudyinhungary
AT santabalazs covid19vaccinationcoverageinpatientswithchronicobstructivepulmonarydiseaseacrosssectionalstudyinhungary
AT tomisagabor covid19vaccinationcoverageinpatientswithchronicobstructivepulmonarydiseaseacrosssectionalstudyinhungary
AT szollosigergo covid19vaccinationcoverageinpatientswithchronicobstructivepulmonarydiseaseacrosssectionalstudyinhungary
AT ungvarizoltan covid19vaccinationcoverageinpatientswithchronicobstructivepulmonarydiseaseacrosssectionalstudyinhungary
AT fazekaspongorvince covid19vaccinationcoverageinpatientswithchronicobstructivepulmonarydiseaseacrosssectionalstudyinhungary
AT majordavid covid19vaccinationcoverageinpatientswithchronicobstructivepulmonarydiseaseacrosssectionalstudyinhungary
AT tarantinistefano covid19vaccinationcoverageinpatientswithchronicobstructivepulmonarydiseaseacrosssectionalstudyinhungary
AT vargajanostamas covid19vaccinationcoverageinpatientswithchronicobstructivepulmonarydiseaseacrosssectionalstudyinhungary